Q3 EPS Estimate for Envoy Medical Boosted by Analyst

Envoy Medical, Inc. (NASDAQ:COCH) – Stock analysts at Brookline Capital Management increased their Q3 2025 earnings per share estimates for shares of Envoy Medical in a research report issued to clients and investors on Thursday, October 9th. Brookline Capital Management analyst T. Bussian now forecasts that the company will post earnings of ($0.24) per share for the quarter, up from their prior estimate of ($0.30). The consensus estimate for Envoy Medical’s current full-year earnings is ($1.21) per share. Brookline Capital Management also issued estimates for Envoy Medical’s Q4 2025 earnings at ($0.28) EPS and FY2025 earnings at ($1.13) EPS.

Envoy Medical (NASDAQ:COCH) last issued its quarterly earnings results on Thursday, July 31st. The company reported ($0.32) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.03). The business had revenue of $0.08 million during the quarter, compared to analysts’ expectations of $0.07 million.

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Envoy Medical in a research note on Wednesday, October 8th. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $9.25.

Envoy Medical Stock Performance

Shares of NASDAQ:COCH opened at $0.89 on Monday. Envoy Medical has a one year low of $0.74 and a one year high of $3.09. The stock has a fifty day moving average of $1.20 and a 200-day moving average of $1.38. The company has a market capitalization of $21.07 million, a PE ratio of -0.62 and a beta of 2.09.

Institutional Trading of Envoy Medical

Institutional investors have recently bought and sold shares of the business. NorthRock Partners LLC bought a new stake in Envoy Medical in the 2nd quarter valued at $14,612,000. Focus Partners Wealth acquired a new position in Envoy Medical in the 1st quarter valued at about $276,000. Finally, Arcus Capital Partners LLC acquired a new position in shares of Envoy Medical during the 1st quarter worth approximately $244,000. Institutional investors and hedge funds own 8.59% of the company’s stock.

About Envoy Medical

Envoy Medical, Inc, a hearing health company, provides medical technologies for the hearing loss spectrum. Its products include personal sound amplification devices; hearing aids; Esteem fully implanted active middle ear implants; auditory osseointegrated implants; and Acclaim cochlear implants. The company was formerly known as Envoy Medical Corporation and changed its name to Envoy Medical, Inc in September 2023.